Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 7/20 | 0.79 |
| ▸ | BRAF | P15056 | 11/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HCK | P08631 | 1/20 | 0.55 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16735233 | 0.88 | RAF1 (1.00) | RAF1BRAFPDGFRBPDGFRAKDR | |
| SCHEMBL16735230 | 0.81 | BRAF (1.00) | RAF1BRAFPDGFRBPDGFRAKDR | |
| SCHEMBL16735269 | 0.80 | RAF1 (1.00) | RAF1BRAFPDGFRBPDGFRAKDR | |
| SCHEMBL16735369 | 0.78 | RAF1 (1.00) | RAF1BRAFPDGFRBPDGFRAKDR | |
| SCHEMBL5216137 | 0.78 | KDM4E (0.66) | RAF1BRAFPDGFRBPDGFRAKDR | |
| SCHEMBL16735265 | 0.78 | RAF1 (0.81) | RAF1BRAFPDGFRBPDGFRAKDR | |
| SCHEMBL16735234 | 0.77 | RAF1 (1.00) | RAF1BRAFPDGFRBPDGFRAKDR | |
| SCHEMBL16735360 | 0.76 | RAF1 (0.79) | RAF1BRAFPDGFRBPDGFRAKDR | |
| SCHEMBL16735363 | 0.76 | RAF1 (0.64) | RAF1BRAFPDGFRBPDGFRAKDR | |
| SCHEMBL16137327 | 0.76 | DDR2 (0.62) | RAF1BRAFHCKNR2C2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388165-B2 | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2016-07-12 | — | — | US | claimed |
| US-20150191450-A1 | ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2015-07-09 | — | — | US | claimed |
| US-9388165-B2 | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2016-07-12 | — | — | US | disclosed |
| US-9388165-B2 | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2016-07-12 | — | — | US | disclosed |
| US-20150191450-A1 | ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2015-07-09 | — | — | US | disclosed |
| US-20150191450-A1 | ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2015-07-09 | — | — | US | disclosed |
| EP-2876107-A1 | ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2015-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191450-A1 | ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CSNK1A1, MAP3K5, MAP4K2 | RAF1 96/4885BRAF 204/4885PDGFRB 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.